HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Strategy Retains Nasdaq 100 Spot Amid Growing Scrutiny of Bitcoin Treasury Model 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Genetic testing company 23andMe Holding Co. (NASDAQ: ME) has filed for Chapter 11 bankruptcy in the U.S. Bankruptcy Court for the Eastern District of Missouri. The company announced the move on Monday, aiming to facilitate a court-supervised sale process while continuing operations.
The bankruptcy filing follows the rejection of a buyout offer from company co-founder Anne Wojcicki and her affiliates. Wojcicki has since stepped down as CEO but will stay on the board. Joe Selsavage has been appointed interim CEO to lead the company through the restructuring phase.
Facing mounting financial pressure and legal issues tied to a 2023 cybersecurity breach, 23andMe cited the Chapter 11 process as a necessary step to stabilize the business, reduce costs, and resolve outstanding liabilities. As part of the filing, the company secured $35 million in debtor-in-possession financing from JMB Capital Partners to maintain operations throughout the proceedings.
Despite the bankruptcy, 23andMe emphasized that customer data privacy and protection will remain intact and are a top priority during any asset sale. The company plans to solicit bids over a 45-day period, with any final transaction requiring regulatory approval.
Once a pioneer in at-home DNA testing, 23andMe has struggled with declining revenues, rising costs, and reputational damage following last year’s cyber incident. The firm is now seeking a buyer to preserve its core assets and continue its mission of delivering personalized genetic health insights.
This latest development marks a turning point for the once high-flying biotech firm, underscoring broader challenges in the consumer healthtech sector. Investors and customers alike will be closely watching as the company navigates its next chapter under bankruptcy protection.
